Superworth

Royalty Pharma EV/EBIT RPRX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2021.

Today, Nov 3, 2026
31.2×
5-year median
24.0×
Against its 5-year history
85th
percentile: 0 is its lowest day, 100 its highest
5-year range
14.4× to 38.9×
Peer median
30.6×

Royalty Pharma's EV/EBIT is 31.2× as of Nov 3, 2026.

That is above its 5-year median of 24.0×, higher than on 85% of days in the last 5 years.

Over that time it ranged from 14.4× in May 2025 to 38.9× in Nov 2022.

The median for 10 healthcare stocks of a similar size is 30.6×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far31.2×21.7×31.4×
202521.9×14.4×22.3×
202415.9×15.7×27.5×
202325.1×23.0×35.9×
202236.0×20.3×38.9×
202120.5×16.5×24.5×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

CompanyEV/EBIT
RPRXRoyalty Pharma31.2×
BIIBBiogen39.2×
GEHCGE HealthCare Technologies14.9×
ONCBeOne Medicines40.2×
IQVIQVIA25.4×
ZTSZoetis11.9×
ILMNIllumina36.6×
MTDMettler-Toledo International30.6×
RMDResMed17.2×
WATWaters128×
MDLNMedlinen/m
Peer median30.6×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.